Abstract: The present disclosure relates to a composition for preventing alopecia and accelerating hair growth, including an ingredient inducing new development of hair or accelerating hair growth. The composition for preventing alopecia and accelerating hair growth reduces a period of transition from a telogen stage to an anagen stage in the hair growth cycle to accelerate hair growth and to delay a transition to a catagen stage, and thus provides excellent effects of preventing alopecia and accelerating hair growth. In addition, the composition is safe to the human body, causes no side effect and provides excellent effects of accelerating proliferation of dermal papilla cells and enhancing hair elasticity.

Abstract: A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains and active ingredient compound with a backbone structure of formula (I).

Abstract: An AMP-activated protein kinase (AMPK) activating agent comprises 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-b-D-glucose (“GHG”) as an active ingredient. The AMPK activating agent can be a GHG-containing composition wherein the GHG is an active ingredient of the composition. The GHG-containing composition can be derived from Kenyan purple tea, whose scientific name is Camellia sinensis, variety name: TRFK306. An effective amount of the GHG can be administered to a cell to activate the AMPK. Drinks, foods, and cosmetics can have the GHG as an active ingredient.

Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.

Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (CI). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.

Abstract: In some aspects, the disclosure provides methods for modulating mitochondrial transport of serine in a cell, the methods comprising modulating expression or activity of one or more sideroflexins. In some aspects, methods of identifying agents that modulate sideroflexin expression or activity are provided. In some aspects, methods of treating cancer are provided.

Abstract: The disclosure provides polymeric compounds that inhibit binding of an amyloid-?-oligomer to cellular prion protein, methods for identifying such compounds, and their therapeutic use. In particular, the present disclosure provides a collection of anionic polymers and methods of using these compounds to treat amyloid-related disorders, e.g., Alzheimer's disease.

Abstract: The present invention provides a composition for prevention and/or improvement of pneumonia. More specifically, the present invention provides a composition for prevention and/or improvement of pneumonia and a symptom associated with pneumonia in a subject, comprising molecular hydrogen as an active ingredient.

Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.

Abstract: Disclosed herein are compositions, constructs, cassettes, vectors, cells, nucleic acids, peptides, proteins, protocols and methods for reducing cholesterol and lipid buildup in mammalian subjects, via gene and/or cell therapeutic treatments. In many embodiments, the disclosed compositions, cells, constructs, cassettes, vectors, nucleic acids, peptides, proteins, protocols and methods may help to reduce lipid levels in mammals. In one embodiment, the disclosed compositions, cells, constructs, cassettes, vectors, nucleic acids, peptides, proteins, protocols and methods are useful in reducing lipid build-up, especially cholesterol, in liver cells.

Abstract: The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.

Abstract: Methods and compositions for treating aging-related diseases as well as liver regeneration, prevention of liver degeneration, and maintenance of liver are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.

Abstract: Provided herein are methods of stimulating or increasing the proliferation of a Treg cell, compositions including a population of Treg cells generated by these methods, and methods of treating a subject using these compositions.

Abstract: The present disclosure provides for conversion-resistant CAR regulatory T cells (Tregs) and bi-specific antibodies, and methods to use these Tregs and antibodies for the treatment of autoimmune diseases and for prevention of organ transplant rejection.

Abstract: The present disclosure generally relates to, inter alia, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions such as cancers.

Abstract: The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4(+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.

Abstract: A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.

Abstract: The invention provides bispecific chimeric antigen receptors (CARs) targeting CD37 and CD19, as well as related molecules, immune cells including the same, compositions thereof, and their methods of use. The invention further provides methods for treating a disease or disorder, e.g., a cancer.

Abstract: The present invention relates to compositions comprising engineered allogenic immune cells endowed with Chimeric Antigen Receptors (CAR), in particular a CAR specific for CD123 and CLL1 for treating AML patients with adverse genetic risk.

Abstract: The present disclosure provides methods for treating cancer. Methods for treating cancer can include administration of pentostatin and cyclophosphamide followed by administration of manufactured T cells. The present disclosure further provides for methods for producing such manufactured T cells, said manufactured T cells and compositions comprising said manufactured T cells.

Abstract: The present invention refers to exosomes obtained from fibro-adipogenic progenitors (FAPs) previously exposed to histone deacetylase (HDAC) inhibitors. It also relatesto such exosomes for the use in the treatment of muscular dystrophies, in particular in the treatment of Duchenne Muscular Dystrophy. Pharmaceutical compositions comprising such exosomes and their medical uses are also within the scope of the present invention.

Abstract: A method of making mammalian chondroblast cells or progenitors thereof and a method for their use. A method of making exosomes and signaling factors and a method for their use.

Abstract: A flowable birth tissue composition fabricated from birth tissue is provided. Methods of processing a mammal's placental tissue to form a flowable birth tissue composition are provided. Various methods of treatment and uses are also provided.

Abstract: A flowable birth tissue composition fabricated from birth tissue is provided. Methods of processing a mammal's placental tissue to form a flowable birth tissue composition are provided. Various methods of treatment and uses are also provided.

Abstract: This invention relates, at least in part, to engineered antimicrobial probiotics for the prevention or treatment of Clostridia perfringens-induced necrotic enteritis in animals and related methods. In an embodiment, a composition for treatment of chickens is included. The composition can include a bacterium originally isolated from the small intestinal tract of healthy chickens and can be genetically engineered with two exogenous polynucleotides. A first exogenous polynucleotide can include a heterologous promoter and a polynucleotide that encodes an antimicrobial protein. A second exogenous polynucleotide can include a heterologous promoter and a polynucleotide that encodes proteins that function to secrete the antimicrobial protein to the extracellular environment. In an embodiment, the antimicrobial peptide can be effective in killing C. perf. inside the gastrointestinal tract of chickens.

Abstract: A composition containing a vital probiotic culture for human or veterinary use as a deodorant for use in pharmacy, human and veterinary medicine, and cosmetics. The preparation contains a single-strain or multi-strain probiotic culture capable of surviving in vital form for a period of a number of months or years in an environment of highly concentrated alcohol. The probiotic culture may be advantageously stabilised, at least partially, by encapsulation in a layer of oil.

Abstract: Provided herein are methods and compositions related to promoting or reducing colonization of spore-forming bacteria in a patient's gut, comprising administering a serotonin receptor agonist or a selective serotonin reuptake inhibitor, respectively. In some aspects, provided herein are methods of modulating lipid and steroid metabolism.

Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat a gastrointestinal disease or disorder. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Anaerostipes hadrus and their uses in treating intestinal diseases or disorders.

Abstract: The present invention relates to a Leuconostocholzapfelii strain for improvement an intestinal function and a use thereof, since the Leuconostoc holzapfelii strain of the present invention can effectively improve the function of an intestine, application to various fields such as various food compositions, pharmaceutical compositions, compositions for animal feed, etc., including functional food composition, is expected.

Abstract: Implemented new use of probiotics, especially of the Leuconostoc mesenteroides subsp. mesenteroides SD23 strain to be consumed during pregnancy and lactation of obese mother and to partially or totally prevent metabolic alterations caused by a high fat diet both in the mother and the offspring.

Abstract: The present invention relates to a bacterial of the Streptococcus thermophilus species with reference CNRZ160, for use in the prevention and/or treatment of intestinal inflammation in an individual.

Abstract: The present invention relates to non-viable bacteria of the Bifidobacterium bifidum strain SYN-HI-001 deposited under deposit No. DSM 24514, or one or more fragments thereof, for use in therapy, particularly for use in treating a gastrointestinal disorder, such as irritable bowel syndrome. Furthermore, the present invention relates to a composition comprising, as an active ingredient, said non-viable bacteria for use in therapy, particularly for use in treating a gastrointestinal disorder. Also, the present invention relates to a method of preparing non-viable bacteria of the Bifidobacterium bifidum strain SYN-HI-001 deposited under deposit No. DSM 24514, or one or more fragments thereof, and to bacteria obtained by the inventive method for use in therapy, particularly for use in treating a gastrointestinal disorder.

Abstract: The present invention relates to an anti-influenza virus agent comprising Bifidobacterium bifidum as an active ingredient.

Abstract: The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.

Abstract: The present invention disclosure relates to a new probiotic strain of Lactobacillus brevis, isolated from pique and exhibiting anti-cancer properties, as welt as to compositions which contain said strain.

Abstract: Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a recombinant bacterium expressing a crystal protein such as a Bacillus thuringiensis crystal protein (Cry). The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A. The recombinant bacterium may be, for example, a Bacillus subtilis or other Gram-positive bacterium, for instance, a lactic acid fermenting bacterium such as Lactococcus or Lactobacillus. Related compositions and recombinant microorganisms are also described.

Abstract: Cannabinoids and probiotics formulated into a suppository and used to treat urogenital, gastrointestinal or aural infections and/or inflammation by local use of the suppository for a period of time are described.

Abstract: The present invention relates to a biotechnological process for the production of a fermented pollen comprising the inoculation of pollen with at least one lactic bacterium of the species Lactobacillus kunkeei selected from Lactobacillus kunkeei PF12 (DSM 32843), PF13 (DSM 32845) and/or PL 13 (DSM 32844) and the fermentation of the pollen inoculated with said lactic bacterium. The fermented pollen obtained has nutritional and organoleptic properties similar to bee bread naturally produced inside the honeycomb of the beehive and finds application in the food and nutraceutical field. The invention further encompasses Lactobacillus kunkeei PF12 (DSM 32843), PF13 (DSM 32845) and/or PL 13 (DSM 32844) as such and compositions comprising these strains.

Abstract: At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

Abstract: Provided is a recombinant virus comprising a fragment of exogenous polynucleotides encoding suppressor of cytokine signaling 4 (SOCS4) or a functional fragment thereof, wherein the recombinant vims expresses SOCS4 or the functional fragment once replication in a cell. Also provided are use of a recombinant oncolytic virus for preparation of therapeutic drugs of cancer and side effects of virus infection.

Abstract: Disclosed herein, in certain embodiments, is a method of inhibiting or treating a cancer with use of a TNF expressing myxoma virus. Also disclosed herein are methods of inhibiting or treating a cancer with use of a mononuclear peripheral blood cells and/or a bone marrow cells treated with a TNF-expressing myxoma virus. Some aspects relate to engineered myxoma virus and pharmaceutical compositions for use with one or more of the methods described herein.

Abstract: Provided herein are compositions useful for the treatment or prevention of C. difficile-associated disease or C. difficile-associated diarrhea in a subject in need thereof, and delivery systems and package systems comprising the same. Also provided are methods using the compositions, delivery systems, package systems and methods of making the same.

Abstract: The disclosure is a composition for treating, preventing, ameliorating, or suppressing cancer, or inhibiting cancer metastasis, comprising a plant fermentation extract as an active ingredient, wherein the plant fermentation extract comprises a yeast that is viable in an environment at pH 1 and that is capable of forming spores in a complete medium.

Abstract: Problem to be solved: An object of the present invention is to provide a novel fat absorption inhibiting agent. Solution to the problem: The present invention provides a fat absorption inhibiting agent comprising pulverized defatted sesame seeds or a processed product thereof. The present invention also provides a fat absorption inhibiting agent comprising defatted sesame seeds having a 50th percentile particle size of 1 to 200 ?m as determined by laser diffraction/scattering and a compressibility index of to 80%. The fat absorption inhibiting agent of the present invention preferably has lipase inhibitory activity. The present invention also provides a food comprising the agent. The present invention also provides defatted sesame seeds having a 50th percentile particle size of 1 to 200 ?m as determined by laser diffraction/scattering and a compressibility index of 30 to 80%.

Abstract: The present invention relates to compositions based on nanodispersions which are preferably further processed to electrospun fibers comprising such nanodispersions. The nanodispersions may optionally contain birch bark extract. The electrospun fibers can be used in particular for the treatment of wounds. For this purpose the compositions containing electrospun fibers are preferably applied as such or in a spray or a foam.

Abstract: The present invention relates to a composition for oral use comprising an extract of Tamarindus indica, hyaluronic acid and/or its salts and at least one block copolymer of ethylene oxide and propylene oxide for the treatment of gastric and oesophageal diseases, in particular gastroesophageal reflux.

Abstract: The present invention relates to the abietane diterpene taxodione and to rosemary stem extract containing taxodione for their use in treating a muscle wasting diseases and/or disorders; it also relates to the use of taxodione as natural meat preserver.

Abstract: Disclosed herein include methods, compositions, and kits suitable for use in treating or reducing a symptom of a urinary condition, such as, for example, overactive bladder and urinary incontinence. The method can comprise administration of a composition comprising herbal extract preparations.

Abstract: A pharmaceutical product of the present invention contains plant parts obtained from the neem tree Azadirachta indica or active ingredients derived from such plant parts for use in treating, preventing and/or alleviating symptoms of restless legs syndrome.